Member Info for Ghia

and since they have nothing to put into clinical trials yet are probably at least 5months away from releasing anything.

Agreed this had pump and dump written all over it feel sorry for anyone getting burnt

My perception is that whilst some trusts are recruiting well others may be more focused on trials which are being pushed stronger by the government.

I must stress this is just my perception from media and a few discussions with people I know within the NHS.

It's encouraging that you have a differing view. I still expect the trial to be sticking to the 8week schedule I was optimistically hoping for a 6 week time frame.

I think that's the key part we still have a 4-5week head start to all the drugs moving onto ACCORD.

What is perhaps concerning is the perception that we are struggling to reach our 100patient quota and all these extra trials are diluting the pool of potential candidates. It would be nice to have an update on patient numbers as we are guessing at the moment.

I think around 53p is the lowest I have seen so far today

Thanks for perfectly proving my point extend the window earlier by two days and what do you see. You chose to start from the 23rd to paint an overly negative view.

21 April 52.5
22 April 58

BorGenBio have been confirmed as on the ACCORD trial. I'm not sure if the mentions of IQVIA and AstraZeneca mean they also have two potential treatments for the trial completing the 3.

Or if they are contributing to the partnership with the NIHR to provide technical resource to run the trials.

that's a very windowed approach at viewing things.

ODX where down 7 today NCYT where level today etc etc

The market is volatile there are swings left right and centre

Hopefully the bigger picture view will benefit all here

No mention of Synairgen as one of the 3 drugs entering the ACCORD trial though in that article.

Thanks Henners,

It was the second part of this phrase that I thought was similar to our approach.

"blocking viral entry and enhancing the anti-viral type I interferon response"

I think it's important to stress each and everyone one if us owns our own investment decisions. We are not qualified to give investment advice to each other and people should not be investing solely on what they read on these boards.

If you feel uncomfortable with your current investment only you can decide how to proceed no one here will hold it against you.

To all poster new and old lets continue to post research that we find whether it paints the company in a positive or negative light all is welcome for review.

This morning could have been such a different story based on the news from Matt H yesterday, both ways.

Whilst disappointed he was not referencing us, I am also relieved that the reference is to another drug which is only just beginning the phase 2 clinical trial journey and appears to have the same goal as ours in stimulating the interferon response.

Good Luck All

Miggy I wasn't having a dig at you and I appreciated you posting the response. The discussion was around discouraging others to spam the CEO it's less likely we would get any response then through the already established communications with certain holders.

Frustrating this is drifting but in these times you just have to have faith in the research, in my eyes nothing has changed to negatively effect our chances.

Henners007 I don't pretend to understand the Bergenbio approach but am I correct in saying the end result is to try and achieve the same thing as Synairgen. To stimulate the interferon response?

Yes the thought of over enthusiastic Pi's spamming email in boxes is a little frustrating.

I genuinely believe the likes of Sharesting and Miggy are using their communication channels with Richard with respect.

It was sad what happened to the Nurse on Twitter when she was posting trial updates in excitement.

If someone does choose to email the communications team could you ask them why the official Synairgen twitter account has been suspended, perhaps they are unaware of this fact.

Audited results are exactly that they require external auditing. Due to Covid 19 I expect there is a delay in getting an external audit completed on the accounts.

Every year the company I work for has external auditors visit site to double check on inventory etc before release of audited accounts to the market.

Unfortunately we are easy prey for them at the moment in a period of trading lower before news lands.

It's unrealistic to expect the company to update on every move the video last week was a great boost for morale for all here.

We are at the beginning of a 4week RNS window patience is key.

The question is where have the placing shares and Lansdowne shares ended up? That's a lot of shares to have been absorbed by PI's.

Intrepid thats not true, Novacyt where caught by surprise being first in the game. The manufacturers late to the game have had time to plan their manufacturing stream. GDR for instance has capacity of 10,000 assays per hour.

So yes manufacturing bottlenecks are what will prevent sales growth here and across many stocks but I would not say that Novacyt are ahead of the game.

SO last night the government was on about the new ACCORD Trial initiative. BerGenBio was the company alluded too. Interferons again!

https://www.bergenbio.com/ceo-letter-covid-19-clinical-trial/

"At the same time, we have been working hard to see how we might help in the fight against COVID-19 more directly. On 28 April we announced our participation in a new UK national multi-centre randomised Phase 2 clinical trial initiative called ACCORD (ACcelerating COVID-19 Research & Development platform). BerGenBio’s bemcentinib was selected as the first candidate to be tested for its efficacy and safety in patients hospitalised with COVID-19.
Whilst our clinical focus for bemcentinib, a highly selective and potent inhibitor of AXL kinase, has been on the treatment of cancer, we have been aware of bemcentinib’s anti-viral potential for some time, as demonstrated in preclinical models against viruses such as Ebola and Zika, with recent data expanding this to SARS-CoV-2. Bemcentinib selectively inhibits AXL kinase activity, blocking viral entry and enhancing the anti-viral type I interferon response, a key cellular defence mechanism against viral infection."

Oil I suspect all the regulars are researching like mad sniffing around for leads.

To be honest unless we find a new source of information there’s not a lot that can be added to the conversation.

Of the 5 recovery trial drugs and us I’d put my money on us so unless we can find another drug in the later stages of a phase 2 trial I’m optimistic.

However I would have hoped for a stronger finish to the day.

That being said I struggled to buy a few K at 55p towards the close took me a good few mins to get a quote.